Enhanced stability of active substances

Enhanced stability of active substances is a pharmaceutical and pharmacological concept rather than a biological target, receptor, or enzyme. It refers to the preservation of the chemical, physical, and microbiological integrity of an active pharmaceutical ingredient (API) from the time of manufacture through its shelf-life and following administration into the body. Stability is critical for ensuring that a drug maintains its safety and efficacy; degradation can lead to a loss of potency or the formation of toxic byproducts [1]. Strategies to enhance stability include chemical modifications like PEGylation or prodrug design, and formulation techniques such as the use of antioxidants, pH buffers, or advanced delivery systems like nanoparticles and liposomes [2, 3]. Because this term describes a technical attribute of a drug product or its metabolic resistance rather than a specific protein or molecular entity that a drug binds to, it is classified as 'incorrect' in the context of a therapeutic target search [4]. Understanding and achieving stability is a fundamental requirement in regulatory approvals to ensure consistent patient outcomes [1].

Other names

Drug stabilityMetabolic stabilityChemical stabilityPharmaceutical stabilityShelf-life extension

Not applicable; this is a pharmaceutical property or objective rather than a biological mechanism involving a drug-target interaction.